Potential live vaccines for HIV

被引:7
|
作者
Burnett, MS [1 ]
Wang, N [1 ]
Hofmann, M [1 ]
Kitto, GB [1 ]
机构
[1] Univ Texas, Inst Mol & Cellular Biol, Dept Chem & Biochem, Austin, TX 78712 USA
基金
美国国家卫生研究院;
关键词
salmonella; reverse transcriptase; mucosal IgA;
D O I
10.1016/S0264-410X(00)00303-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Potential live vaccines for HIV were developed using an Lpp-OmpA system to target an HIV antigen, reverse transcriptase, or an immunodominant epitope of this enzyme, to the outer membrane of an attenuated strain of Salmonella SL3261. These live vaccines were administered orally to mice, and fecal IgA and helper T cell responses were measured. Results indicated a fecal IgA response specific to HIV reverse transcriptase, as well as a reverse transcriptase-specific helper T cell response, as measured by proliferation assays. Additionally, tests with the epitope vaccines showed a selective cytotoxic CD8 T cell response. These results suggest that this method of antigen targeting to the outer membrane of attenuated bacterial vectors is very promising not only for HIV vaccine development, but also for antigens from other viral or bacterial pathogens, which could be inserted into the Lpp-OmpA protein construct, to elicit mucosal IgA and T cell responses. (C) 2000 Published by Elsevier Science Ltd.
引用
收藏
页码:735 / 742
页数:8
相关论文
共 50 条
  • [1] Potential live vaccines for HIV (vol 19, pg 735, 2001)
    Burnett, MS
    Wang, N
    Hofmann, M
    Kitto, GB
    [J]. VACCINE, 2001, 19 (27) : 3796 - 3796
  • [2] Live HIV vaccines — How safe?
    Ulf Dittmer
    Christiane Stahl-Hennig
    Gerhard Hunsmann
    [J]. Nature Medicine, 1997, 3 : 816 - 816
  • [3] Live HIV vaccines - How safe?
    Dittmer, U
    StahlHennig, C
    Hunsmann, G
    [J]. NATURE MEDICINE, 1997, 3 (08) : 816 - 816
  • [4] Recombinant rabies virus as potential live-viral Vaccines for HIV-1
    Schnell, MJ
    Foley, HD
    Siler, CA
    McGettigan, JP
    Dietzschold, B
    Pomerantz, RJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) : 3544 - 3549
  • [5] Evolution of Live-Attenuated HIV Vaccines
    Berkhout, Ben
    [J]. BIOPHARM INTERNATIONAL, 2011, 24 (01) : S4 - S8
  • [6] Improvements in live-attenuated HIV vaccines?
    不详
    [J]. IMMUNOLOGY TODAY, 1996, 17 (09): : 401 - 401
  • [7] Live attenuated HIV vaccines: pitfalls and prospects
    Whitney, JB
    Ruprecht, RM
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2004, 17 (01) : 17 - 26
  • [8] Therapeutic live vaccines as a potential anticancer strategy
    Bolhassani, Azam
    Zahedifard, Farnaz
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (08) : 1733 - 1743
  • [9] Safety of live, attenuated oral vaccines in HIV-infected Zambian adults Oral vaccines in HIV
    Banda, Rose
    Yambayamba, Vera
    Lalusha, Bwalya Daka
    Sinkala, Edford
    Kapulu, Melissa Chola
    Kelly, Paul
    [J]. VACCINE, 2012, 30 (38) : 5656 - 5660
  • [10] Immunity and protection by live attenuated HIV/SIV vaccines
    Wodarz, Dominik
    [J]. VIROLOGY, 2008, 378 (02) : 299 - 305